Craig HENDRIX, Johns Hopkins University, Baltimore, USA
"HIV pre-exposure prophylaxis (PrEP) with tenofovir-containing regimens has now been tested in seven randomized clinical trials in diverse risk populations. The degree of HIV protection varies widely, from no protection to 92% protection in some study subsets. What are the causes for this tremendous variability in outcomes? What do these studies tell us about managing PrEP in individuals? How can it be instructive for the next generation of PrEP agents?"
Dr. Hendrix's primary research focus is pharmacology of HIV pre-exposure prophylaxis (PrEP). This involves development of both oral and topical drugs for PrEP, their concentration-response relationships in prevention of HIV infection, and development of methods to quantitatively address these areas of research.
Microbicide (vaginal and rectal application of PrEP drugs) research interests include development of methods to study the distribution of microbicides and HIV in the distal colon and the female genital tract using radiology techniques and direct sampling. He has served as principal investigator for numerous pharmacokinetically-focused microbicide studies in the US and Africa. He has applied these methods in several developmental studies designed to optimize new dosing formulations for both rectal and vaginal microbicide products.
He has been the clinical pharmacologist for most of the randomized controlled PrEP trials using antiretroviral drugs. In addition, he has been similarly involved with numerous other developmental PrEP studies in the NIH-funded HIV Prevention Trials Network (HPTN) and Microbicide Trials Network (MTN). Using data from these studies, he is currently interested in pharmacological assessments of adherence as well as the assessment of the concentration-response relationship within and among these studies to address future trial design and application of trial results to clinical practice.
« Go Back